아큐먼 파마슈티컬스(ABOS)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.58 (+0.39%), 시가총액 $0.17B, 52주 최저~최고 $1.00 ~ $3.37.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquart
아큐먼 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
아큐먼 파마슈티컬스의 현재 주가는 $2.58 (+0.39%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
아큐먼 파마슈티컬스의 시가총액은 약 $0.17B입니다.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug ca